EyePoint's drug for age-related eye disease fails late-stage trial, shares tank - Reuters
EyePoint's drug for age-related eye disease fails late-stage trial, shares tank Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPS0pNQnFBWENtcFppVm1lNnZ1RnVRV3pYT2luc2RnMk9QYVFrb1g5VkVQNXlDbXdRMnR2Yk54Ym9mX0xiSnJPbDI1T29GNTVNeGFuUFFzZDZ4OXQxcGo2QlVkRU1velpHUTQ4WGdrcGdaTHlmMkUxVWlQMVBkWFNmVFdBMzBzaGYwZlQ0MFF5ak1qWC1IOGxtN2RQdGhhVkFBWFJfbDZZMEFIbF9FRVVjSG83NWdsTzFmVF9wMGtySTFCQQ?oc=5" target="_blank">EyePoint's drug for age-related eye disease fails late-stage trial, shares tank</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMUS FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMUS FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PMNvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom - Reuters
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom Reuters
October 8, 2026 at 06:18 PMPepsiCo running out of time to meet Elliott-inspired targets as GLP-1 threat intensifies - Reuters
PepsiCo running out of time to meet Elliott-inspired targets as GLP-1 threat intensifies Reuters
October 7, 2026 at 11:36 AMHalozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PM